This is a randomised, double-blind, placebo controlled study on a cannabis-based medicine extract (CannTrust CBD Oil), in patients with Amyotrophic Lateral Sclerosis or Motor Neurone Disease. Participants will be randomised in a 1:1 ratio to receive CannTrust CBD Oil or placebo (both in capsules). The treatment duration is 6 months with one-month safety follow up. Participants will be checked every month either face to face or via telephone and will be assessed to collect data for study objectives such as ALSFRS-R, Forced Vital Capacity, pain and spasticity score, and quality of life. Thirty (30) participants will be randomised.
Study Type :
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
A Randomised, Double-blind, Single-centre Study on the Safety, Tolerability and Efficacy of Cannabis Based Medicine Extract (CannTrust CBD Oil) in Slowing the Disease Progression in Amyotrophic Lateral Sclerosis or Motor Neurone Disease Patients
Estimated Study Start Date :
Estimated Primary Completion Date :
Estimated Study Completion Date :